@Tesla_AI@Tesla
FSD 14.2.2 reacted to emergency vehicle on the other side of the road and tried to pull over to the gas station. Hopefully, this bug is fixed is 14.2.2.1.
FSD 14.2.1.25 overview
Very smooth, definitely at this point, better than 13.2.9 however, there's still few things if improved can make the experience day and night better. Hesitation during lane changes & bad navigation leads to disengagement often than 13.2.9.
@Tesla@Tesla_AI
@BLKMDL3@Tesla_AI Definitely smoother than 14.1.4 and yes, no more brake stabbing for leaves but overall not so impressive, at least for me. Jitters while taking left turns, one sided lane hugging, mis-matching speed limits, indecisive for left turns, getting out of parking lot = park again.
Fresh at @ISEV_JExBio - Ofir, a joint student with Prof. Angel Porgador from @bengurionu has gone over hundreds of papesr to come up with this comprehensive review discussing the convergence of CAR technologies and EVs from T or NK cells. Take a look at https://t.co/T6Dmyf0sxF
In this new study published in @cddpress we demonstrate that cancer cells carrying mutant p53 exhibit radiosensitivity to alpha-particles-based radiotherapy. This sensitivity is further enhanced when combined with p53 restoration (using APR-246). #p53 https://t.co/YhWBbbCu4w
Yesterday, Dr. Ishai Luz, our research associate, fought off Hammas invaders attacking the Kibbutz nearby Gaza where he lives with his family. Risking his life while saving many. We face delicate times. Sadly, a lot of blood will be shed on both sides. Will we ever learn?
Last 48 hours to register to this epic meeting! Four exciting days with top EVs researchers from all around the world. Hit the registration button and hop on. #EVFF2023
https://t.co/Q7MnlPxo3H
๐ซง๐ฎ๐งช๐งฟ๐บ๐ฅ๐
Together with @yochai_wolf, we are expanding our T-cell mRNA engineering efforts and looking for scientists (Ph.D.) with expertise in Immunology and molecular biology for collaborative research with a big pharma company. don't hesitate to get in touch.
1/ Our new publication is finally out at @FrontOncology ๐ค We suggest a new modality for recurrent #Glioblastoma by combining DaRT and Avastin. This exciting new treatment stems from our fruitful collaboration with the group led by Vered Domankevich from @AlphaTauMedical and